Investments
Details of our portfolio appear below.
- Acrobot -
Acrobot, a spin-out from Imperial College London, is developing systems to assist minimally-invasive surgery in orthopaedics. It was founded by Brian Davies, Professor of Medical Robotics in the Department of Mechanical Engineering and Justin Cobb, Professor of Orthopaedics and a leading Orthopaedic Surgeon. Acrobot’s product portfolio includes Acrobot Modeller, in which a CT scan is used to produce a patient specific 3D model of the bone; Acrobot Planner, which offers pre-operative surgical planning and visualisation software; the Acrobot Navigation System, which provides computer-assistance by tracking the spatial locations of tools and patient and depicting them against a pre-operative plan on a computer screen to be used by the surgeon as guidance; and the Acrobot Sculptor Robotic System, a motorised programmable device which uses ‘active constraint’ to prevent a surgeon accidentally moving outside a specified area. LTF co-led a syndicate investing £2.6m in July 2007.
For more information, please see latest news, our press release and www.acrobot.co.uk.
- ApplianSys -
ApplianSys specialises in server appliances, taking the central role in designing and building the appliance. Server appliances are servers with hardware and software designed and integrated for a specific task in a network. The server appliance approach offers a number of customer benefits compared with installing standard software applications on general purpose servers. These benefits include reduced costs of ownership and enhanced security. Savings are derived from lower upfront configuration and downstream maintenance costs, as well as lower costs associated with space, power and heat. With server appliances dedicated to one application the platform is also inherently secure. The London Technology Fund co-led a funding round of £620k in January 2007. A second close on 28 February 2007 took the total amount raised by ApplianSys to £720k.
For more information, please see latest news, our press release and www.appliansys.com.
- deltaDOT -
deltaDOT Ltd is a life science company that is developing and commercialising innovative enabling technologies for the separation and analysis of biomolecules. It was founded in 2000 and is a spin out from Imperial College of Science, Technology and Medicine, London. deltaDOT's core label free analysis technology, coupled with proprietary software algorithms, forms the technical basis of its products. This label free technology enables higher quality and faster separations compared to existing technologies. The increased performance enables the direct monitoring of unlabelled biomolecules, reducing the cost per analysis compared to conventional methods. deltaDOT addresses biomolecular separation applications within pharmaceutical, biotechnology, biodefence, food and drink quality, forensic science, diagnostic and academic markets. The London Technology Fund participated in a funding round of £6m in March 2006.
For more information, please see latest news, our press release and www.deltadot.com.
- Dexela -
Dexela is developing 3-D X-ray imaging technology known as Tomosynthesis and is initially focused on the early detection of breast cancer. The early detection of breast cancer using screening mammography significantly reduces mortality. However, conventional mammography still has a considerable rate of both false negatives and false positives, particularly in young women. Dexela’s innovative approach aims to reduce these false negatives and false positives, allowing the earlier detection of cancer while reducing the occurrence of call-backs. Dexela has developed techniques to acquire, process and visualise data and aims to play a central role in this field through collaborative agreements with medical device manufacturers. LTF invested in Dexela in July 2008 as part of a syndicate, including Close Ventures, which invested over £2.6m in aggregate.
For more information, please see latest news, our press release and www.dexelaimaging.com.
- Dynamic IT Management Services -
Dynamic IT Management Services is a supplier of specialist software for the foreign exchange market. Dynamic IT has developed a trade notification product, TradeSTP, which enables banks and brokers to deliver foreign exchange trade notifications directly to their clients’ applications. This system of ‘straight through processing’ offers enhanced speed and accuracy by eliminating the delay and risk of error associated with manual updating. TradeSTP has the potential to be a key component of the service offered to foreign exchange clients by banks and brokers. The London Technology Fund led a funding round of £800k in 2006 and has subsequently announced a partial exit.
For more information, please see latest news and our press release.
- Immune Targeting Systems -
Immune Targeting Systems (ITS) Ltd is a London based biotech company developing synthetic vaccines for mutating viruses. These novel vaccines will target the prevention and treatment of major life-threatening viral infections of global impact, including pandemic and seasonal influenza, HIV/AIDS and Hepatitis-C. The technologies encompass the fluoropeptide antigen delivery system and an in-silico / in-vitro method for identifying and validating highly conserved and relevant vaccine components. Unlike conventional vaccine technologies the fluoropeptide approach permits the targeting of genetically diverse mutation prone viruses where cellular immunity is linked to disease protection. Fluoropeptides promote robust antiviral cellular immunity to highly conserved viral components which is known to improve clinical outcomes (flu) and is correlated with disease protection (HIV / HCV). The London Technology Fund participated in a funding round of £4m in July 2007. This was ITS’s first significant round of funding and LTF was the only UK investor in an international syndicate including Novartis Venture Fund (Switzerland), HealthCap (Sweden) and Truffle Capital (France). Following this investment ITS is working to expedite its lead program into the clinic. This vaccine is a universal influenza-A vaccine targeting all potential seasonal & pandemic influenza-A strains.
For more information, please see latest news, our press release and www.its-innovation.co.uk.
- Intellistream -
Intellistream has developed a platform for deploying interactive mobile video applications. This platform, Unistream™, was initially developed to operate over the video calling feature built into all 3G handsets, but has been expanded to cover IP-based smart-phone handsets (such as those which can use both 2.5G or 3G networks) via a downloaded client. The Company is initially targeting the security and safety market offering remote access to CCTV cameras from mobile phones. Possible applications include the corporate security markets, both SME businesses and also as an adjunct to existing large corporate and public security installations, and the domestic security markets. The London Technology Fund led a funding round of £355k in November 2006. In April 2008 LTF announced the first close of a further funding round of up to £1m and this was followed by the appointment of a new chairman.
For more information, please see latest news and www.intellistream.co.uk.
Please be sure to read this important legal information.